Current Price
Target Price
Achilles Therapeutics Plc, a clinical-stage immuno-oncology biopharmaceutical company, develops precision T-cell therapies to treat various types of solid tumors. The company is headquartered in London, the United Kingdo...|
e.g. Promoter holding
Loading chart...
Analyst consensus EPS and Revenue forecasts.
| Metric (B) | FY 2023 | FY 2023 | FY 2023 | FY 2023 | FY 2024 | FY 2024 | FY 2024 | FY 2024 | FY 2025 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| $-0.40 | $-0.42 | $-0.40 | $-0.14 | $-0.46 | $-0.41 | $-0.41 | $-0.18 | $0.00 | $-0.12 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | -1.2% | +85.9% | — | +86.2% |
| S.No. | Name | Symbol | Market Cap | P/E | P/B | Profit Margin | Op. Margin | ROE | Rev. Growth |
|---|---|---|---|---|---|---|---|---|---|
| 1. | KKezar Life | KZR | $53.86M | — | 0.77 | — | — | -59.90% | — |
| 2. | AAcrivon Th... | ACRV | $62.14M | — | 0.72 | — | — | -64.60% | — |
| 3. | XXilio Ther... | XLO | $57.04M | 12.42 | 0.84 | -20.90% | -74.90% | -38.20% | -47.60% |
| 4. | PPliant The... | PLRX | $43.21M | — | 0.34 | — | — | -50.30% | -100.00% |
| 5. | AAlterity T... | ATHE | $37.42M | — | 1.28 | — | -695.00% | -55.00% | -79.00% |
Consolidated Figures in Millions / View Standalone.
| Quarter (M) | Dec 22 | Mar 23 | Jun 23 | Sep 23 | Dec 23 | Mar 24 | Jun 24 | Sep 24 |
|---|---|---|---|---|---|---|---|---|
Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
COGS | 0.84 | 0 | 1.3 | 1.2 | 0 | 1.18 | 1.18 | 0 |
Gross Profit | -0.84 | 0 | -1.3 | -1.2 | 0 | -1.18 | -1.18 | 0 |
Gross Profit % | - | - | - | - | - | - | - | - |
| 22.83 | 18.55 | 18.09 | 19.1 | 19.51 | 13.11 | 17.8 | 20.42 | |
EBIT | -22.83 | -18.55 | -18.09 | -19.1 | -19.51 | -14.29 | -17.8 | -20.42 |
OPM % | - | - | - | - | - | - | - | - |
Non-Operating Income | -1.18 | 1.09 | 1.21 | 2.39 | 1.39 | 2 | 1.43 | 0.82 |
PBT | -24.02 | -17.46 | -16.88 | -16.71 | -18.13 | -12.29 | -16.37 | -19.6 |
Income Tax | 0.04 | 0.04 | -0.03 | -0.02 | 0 | -0.02 | 0.01 | -0.01 |
Tax Rate % | -0.17% | -0.25% | 0.2% | 0.14% | - | 0.19% | -0.05% | 0.03% |
Net Income | -24.06 | -17.51 | -16.85 | -16.68 | -18.63 | -12.27 | -16.38 | -19.59 |
NPM % | - | - | - | - | - | - | - | - |
Consolidated Figures in Millions / View Standalone.
| Period (M) | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 |
|---|---|---|---|---|---|---|
Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
COGS | 0 | 0.3 | 0.78 | 3.29 | 3.69 | 4.73 |
Gross Profit | 0 | -0.3 | -0.78 | -3.29 | -3.69 | -4.73 |
Gross Profit % | - | - | - | - | - | - |
| 6.89 | 13.78 | 33.73 | 64.19 | 78.38 | 75.25 | |
EBIT | -6.9 | -13.78 | -33.73 | -64.19 | -78.38 | -75.25 |
OPM % | - | - | - | - | - | - |
Non-Operating Income | 0 | -0.21 | 0.53 | 3.13 | 7.32 | 6.08 |
PBT | -6.89 | -13.99 | -33.2 | -61.06 | -71.06 | -69.17 |
Income Tax | 0 | 0.13 | 0 | 0.04 | 0.11 | 0.49 |
Tax Rate % | - | -0.93% | -0.01% | -0.06% | -0.16% | -0.71% |
Net Income | -6.89 | -13.99 | -33.2 | -61.1 | -71.18 | -69.67 |
NPM % | - | - | - | - | - | - |
Consolidated Figures in Millions / View Standalone.
| Period (M) | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 |
|---|---|---|---|---|---|---|
| 10.68 | 97.59 | 177.85 | 266.32 | 173.34 | 131.54 | |
| 0 | 0 | 0 | 0 | 0 | 0 | |
| 0.58 | 2.11 | 28.11 | 28.79 | 20.48 | 0 | |
| 5.15 | 5.97 | 11.71 | 23.56 | 27.87 | 14.09 | |
| -2.46 | -0.47 | 1.25 | -1.57 | -1.33 | 15.82 | |
Total Assets | 13.96 | 105.2 | 218.92 | 317.11 | 220.36 | 161.46 |
| 0 | 0.01 | 0.03 | 0.05 | 0.05 | 0.18 | |
| 12.67 | 101.33 | 189.35 | 289.47 | 196.99 | 142.19 | |
| 0 | 0.49 | 15.98 | 12.26 | 8.58 | 4.62 | |
| 1.29 | 3.37 | 12.9 | 14.63 | 13.48 | 13.46 | |
| 0 | 0 | 0.66 | 0.69 | 1.26 | 1.01 | |
Total Liabilities | 13.96 | 105.2 | 218.92 | 317.11 | 220.36 | 161.46 |
Consolidated Figures in Millions / View Standalone.
| Period (M) | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 |
|---|---|---|---|---|---|---|
| -0.01 | -14.14 | -25.25 | -59.28 | -59.53 | -48.45 | |
| -0.26 | -0.94 | -11.85 | -7.63 | -7.51 | 0 | |
| 0.01 | 93.62 | 113.7 | 0.16 | 0 | 0.01 | |
Net CFNet Cash Flow | -0.25 | 78.54 | 76.61 | -66.76 | -67.05 | -48.44 |
FCFFree Cash Flow | -0.01 | -15.08 | -37.1 | -66.92 | -67.05 | -49.55 |
Financial ratios and valuation metrics by fiscal year.
| Period | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 |
|---|---|---|---|---|---|---|
| - | -24.5% | -22.8% | -25.5% | -29.3% | -41.1% | |
| - | 0.00 | 0.08 | 0.04 | 0.04 | 0.03 | |
| 10.40 | 26.72 | 11.30 | 14.90 | 10.93 | 8.57 | |
| - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Cash Conversion | 0.00 | 1.01 | 0.76 | 0.97 | 0.84 | 0.70 |
Payout Ratio | - | - | - | - | - | - |
| - | - | - | - | - | - | |
| - | - | - | - | - | - | |
| - | - | - | - | - | - | |
| 2.00 | 4.00 | 2.00 | 3.00 | 3.00 | 2.00 | |
| - | - | - | - | - | - | |
| 0.00 | 50.00 | 50.00 | 50.00 | 50.00 | 50.00 | |
| - | - | - | - | - | - |
Note: These ratios and scores are calculated using publicly available financial data and may differ from other sources. Users are advised to verify calculations independently using SEC filings or other official sources before making investment decisions.
Who owns Achilles Therapeutics Plc, from SEC filings
Schedule 13D / 13G filers (5%+), plus stakes Achilles Therapeutics Plc holds in others · open a holder to see each filing
| Holder | Type | Based in | Shares | % of class | Latest filing |
|---|---|---|---|---|---|
| Partnership | DE | 4,100,002 | 9.97% | SC 13G/A · 13 Feb 2025 |
Anyone owning more than 5% must file a Schedule 13D (active) or 13G (passive). Structured filings since December 2024; a holder that drops below 5% files an exit amendment. 13F still covers them in the shareholding table.
| Settlement date | Short shares | Change | Days to cover | Relative size |
|---|---|---|---|---|
| 14 Mar 2025 | 1,504,631 | +214.6% | 1.00 | |
| 28 Feb 2025 | 478,328 | -40.0% | 1.00 | |
| 14 Feb 2025 | 797,854 | +1279.7% | 1.00 | |
| 31 Jan 2025 | 57,830 | -52.7% | 1.00 | |
| 15 Jan 2025 | 122,360 | +0.1% | 1.00 | |
| 31 Dec 2024 | 122,282 | +35.4% | 1.00 | |
| 13 Dec 2024 | 90,323 | -33.9% | 1.00 | |
| 29 Nov 2024 | 136,659 | -36.6% | 1.11 | |
| 15 Nov 2024 | 215,692 | +35.4% | 1.14 | |
| 31 Oct 2024 | 159,245 | -25.1% | 2.25 | |
| 15 Oct 2024 | 212,546 | -40.6% | 1.89 | |
| 30 Sep 2024 | 358,114 | +9201.7% | 1.00 | |
| 13 Sep 2024 | 3,850 | -1.0% | 1.00 | |
| 30 Aug 2024 | 3,888 | -53.8% | 1.00 | |
| 15 Aug 2024 | 8,418 | -56.2% | 1.00 | |
| 31 Jul 2024 | 19,216 | +92.5% | 1.00 | |
| 15 Jul 2024 | 9,984 | -9.7% | 1.00 | |
| 28 Jun 2024 | 11,059 | -52.9% | 1.00 | |
| 14 Jun 2024 | 23,458 | -15.7% | 1.00 | |
| 31 May 2024 | 27,828 | +101.4% | 1.00 | |
| 15 May 2024 | 13,815 | -42.5% | 1.00 | |
| 30 Apr 2024 | 24,042 | -36.4% | 1.00 | |
| 15 Apr 2024 | 37,826 | -49.5% | 1.00 | |
| 28 Mar 2024 | 74,834 | +8.6% | 1.00 |
FINRA consolidated short interest, reported twice a month for every US listing.
Achilles Therapeutics Plc's SEC filings and earnings call transcripts
What recent news says about Achilles Therapeutics Plc, scored for sentiment.